ENLV

Enlivex Ltd. (ENLV) | Rumor.io

Enlivex

ENLV

Attention (50-day avg)0%

Attention rank (50-day avg)#3,468

Bullish sentiment (50-day avg)67%

Price to earnings ratio0

Market capitalization9M

Earnings per share2.1K

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)1.2B

Social

What share of all stock conversation is about ENLV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jul 28

ENLV is priced at $6, trading closer to $3, after a $400m private placement announcement.
The company has entered into a securities purchase agreement to sell $400 million of its ordinary shares or pre-funded warrants to the Rain Foundation.
The private placement priced in at $5 and $6 per share, including token-funded pricing, with an option for another $400 mil buy with same terms.

Generated by AI

Sentiment

Of the messages about ENLV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	94.93% +9.33
Bearish	—	—	100% new	5.07% -9.33

Bullish· Jul 28

The company Enlivex Therapeutics Ltd. (ENLV) has a $400,000,000 buy order that is pending investor approval, which could be seen as bullish by the market.
The stock's minimal short interest, low float of 2.45M, and 55% squeeze risk make it an attractive biotech runner with high volatility potential.
Enlivex's management believes there is value in the stock, having done due diligence, and a private placement of $400 million at higher prices could be seen as a positive acquisition of the company at a higher price.

Bearish· Jul 28

The company's private placement priced lower than the current trading price, which may indicate a loss of investor confidence.
The company's financial health is weak, with a negative net margin, weak cash flow, and a cheap valuation.
The company's price may continue to fall, with some investors expecting it to drop to as low as $2 or $1.50.

Generated by AI

Topics

Of the messages about ENLV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	71.43%	32.56%
Analysts	0%	0%	0%	1.96%
Controversies	100%	100%	14.29%	1.1%
Earnings	0%	0%	14.29%	62.16%
Macro	0%	0%	0%	1.59%
Technical Analysis	0%	0%	0%	0.63%

Earnings· Mar 25

Enlivex Therapeutics Ltd. ($ENLV) reported $1.23B in net income and $25.48 EPS, exceeding typical biotech profiles.
The company's treasury strategy and clinical progress in Allocetra immunotherapy are key drivers of its unusual earnings print.
Market reaction to $ENLV's earnings is expected, with investors watching how the company sustains and builds on this momentum.

Announcements· Mar 25

Enlivex Therapeutics Ltd. (ENLV) reported $1.23B net income and $25.48 EPS, with $2.31B in total assets, marking a significant performance for a clinical-stage biotech company.
The company's unique combination of clinical-stage immunotherapy Allocetra and a treasury strategy tied to prediction markets, such as Rain, is gaining attention and scrutiny from investors and analysts.
ENLV's earnings are being closely watched, with many wondering how the company will explain and sustain its hybrid approach, which is unlike anything seen before in the biotech industry.

Technical Analysis· Nov 24

$ENLV has formed a falling wedge and is currently testing a demand zone, with a potential continuation toward $2.00.
The stock has reclaimed the $1.00 resistance after breaking $0.85 support, with an RSI at 72 suggesting further upside.
A double bottom formation is possible if $ENLV breaks 1.50, with a potential move to 1.65 or more, and the MACD is showing strong momentum.

Generated by AI

Community

Of the messages about ENLV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	92.31%	3.37%
Newcomers	0%	0%	7.69%	96.63%

Regulars· Apr 4

Enlivex Therapeutics Ltd. ($ENLV) has announced a clinical collaboration with Tislelizumab to evaluate combinations of Allocetra and PD1 inhibitor for patients with solid tumors.
The company has filed a form 6-K, which includes full-year 2022 financial results, and provides business updates, including the clinical collaboration with Tislelizumab.
Enlivex Therapeutics Ltd. ($ENLV) has seen an unusually high call volume, with 272 calls in one day, representing 2K% of the 30-day average call volume of 13.3.

Newcomers· Jul 28

Enlivex Therapeutics Ltd. has announced a $400 million private placement of ordinary shares, priced at $5.00 per share, with an institutional investor, offering a return option to require up to an additional $400 million of ordinary shares within 36 months.
The private placement is expected to be a significant catalyst for the company's stock price, with the announcement already causing a sharp decline of -35% in the stock's value, with traders exiting rapidly.
The company's stock price has been volatile, with a pre-market increase of +63% and a market capitalization of $75 million, with a relatively low short interest of 1.1% and a moderate squeeze risk of 55%.

Generated by AI

Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

28d agoYahoo Finance

12 Health Care Stocks Moving In Thursday's After-Market Session - Aethlon Medical (NASDAQ:AEMD), Modular

Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD) stock rose

1mo agoBenzinga

H.C. Wainwright raises Enlivex stock price target to $80 on token gains

1mo agoInvesting.com

Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million

Detailed price information for Enlivex Ltd (ENLV-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Enlivex Secures $400 Million Premium-Priced Private Placement Backed by RAIN Tokens

Detailed price information for Enlivex Ltd (ENLV-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about ENLV also mention

#	Name	Attention
1	Twin Vee PowerCats Co. Common StockVEEE	0%new
2	GE HealthCare Technologies Inc.GEHC	0%0
3	Merck & Co., Inc.MRK	0.01%-0.06
4	RainRAIN	0%new
5	Chain Bridge ICBRG	0%new
6	CL Workshop Group Limited American Depositary SharesNWGL	0%new
7	GSI Technology Inc.GSIT	0%0
8	Airship AI Holdings, Inc.AISP	0%new
9	Bristol-Myers Squibb CompanyBMY	0.01%0
10	TuHURA Biosciences, Inc.HURA	0%0

Enlivex Ltd.

Healthcare
Biotechnology

Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with development efforts centered on conditions such as sepsis and osteoarthritis. The company’s current pipeline includes cell-based therapies for immune-related disorders and degenerative joint disease, reflecting its emphasis on novel approaches to immune modulation. Enlivex Ltd. operates from Ness Ziona, Israel, and serves the healthcare and biopharmaceutical markets through research, clinical development, and therapeutic innovation. The company’s role in the market is to advance experimental treatments that address unmet medical needs in inflammation-driven and immune dysregulation conditions.

Website

Location

14 Einstein Street

Ness Ziona, 7403618

Israel

Social

What share of all stock conversation is about ENLV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Jul 28

ENLV is priced at $6, trading closer to $3, after a $400m private placement announcement.
The company has entered into a securities purchase agreement to sell $400 million of its ordinary shares or pre-funded warrants to the Rain Foundation.
The private placement priced in at $5 and $6 per share, including token-funded pricing, with an option for another $400 mil buy with same terms.

Generated by AI

Sentiment

Of the messages about ENLV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	94.93% +9.33
Bearish	—	—	100% new	5.07% -9.33

Bullish· Jul 28

The company Enlivex Therapeutics Ltd. (ENLV) has a $400,000,000 buy order that is pending investor approval, which could be seen as bullish by the market.
The stock's minimal short interest, low float of 2.45M, and 55% squeeze risk make it an attractive biotech runner with high volatility potential.
Enlivex's management believes there is value in the stock, having done due diligence, and a private placement of $400 million at higher prices could be seen as a positive acquisition of the company at a higher price.

Bearish· Jul 28

The company's private placement priced lower than the current trading price, which may indicate a loss of investor confidence.
The company's financial health is weak, with a negative net margin, weak cash flow, and a cheap valuation.
The company's price may continue to fall, with some investors expecting it to drop to as low as $2 or $1.50.

Generated by AI

Topics

Of the messages about ENLV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	71.43%	32.56%
Analysts	0%	0%	0%	1.96%
Controversies	100%	100%	14.29%	1.1%
Earnings	0%	0%	14.29%	62.16%
Macro	0%	0%	0%	1.59%
Technical Analysis	0%	0%	0%	0.63%

Earnings· Mar 25

Enlivex Therapeutics Ltd. ($ENLV) reported $1.23B in net income and $25.48 EPS, exceeding typical biotech profiles.
The company's treasury strategy and clinical progress in Allocetra immunotherapy are key drivers of its unusual earnings print.
Market reaction to $ENLV's earnings is expected, with investors watching how the company sustains and builds on this momentum.

Announcements· Mar 25

Enlivex Therapeutics Ltd. (ENLV) reported $1.23B net income and $25.48 EPS, with $2.31B in total assets, marking a significant performance for a clinical-stage biotech company.
The company's unique combination of clinical-stage immunotherapy Allocetra and a treasury strategy tied to prediction markets, such as Rain, is gaining attention and scrutiny from investors and analysts.
ENLV's earnings are being closely watched, with many wondering how the company will explain and sustain its hybrid approach, which is unlike anything seen before in the biotech industry.

Technical Analysis· Nov 24

$ENLV has formed a falling wedge and is currently testing a demand zone, with a potential continuation toward $2.00.
The stock has reclaimed the $1.00 resistance after breaking $0.85 support, with an RSI at 72 suggesting further upside.
A double bottom formation is possible if $ENLV breaks 1.50, with a potential move to 1.65 or more, and the MACD is showing strong momentum.

Generated by AI

Community

Of the messages about ENLV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	92.31%	3.37%
Newcomers	0%	0%	7.69%	96.63%

Regulars· Apr 4

Enlivex Therapeutics Ltd. ($ENLV) has announced a clinical collaboration with Tislelizumab to evaluate combinations of Allocetra and PD1 inhibitor for patients with solid tumors.
The company has filed a form 6-K, which includes full-year 2022 financial results, and provides business updates, including the clinical collaboration with Tislelizumab.
Enlivex Therapeutics Ltd. ($ENLV) has seen an unusually high call volume, with 272 calls in one day, representing 2K% of the 30-day average call volume of 13.3.

Newcomers· Jul 28

Enlivex Therapeutics Ltd. has announced a $400 million private placement of ordinary shares, priced at $5.00 per share, with an institutional investor, offering a return option to require up to an additional $400 million of ordinary shares within 36 months.
The private placement is expected to be a significant catalyst for the company's stock price, with the announcement already causing a sharp decline of -35% in the stock's value, with traders exiting rapidly.
The company's stock price has been volatile, with a pre-market increase of +63% and a market capitalization of $75 million, with a relatively low short interest of 1.1% and a moderate squeeze risk of 55%.

Generated by AI

Enlivex

Social

Jul 28

Bullish· Jul 28

Bearish· Jul 28

Earnings· Mar 25

Announcements· Mar 25

Technical Analysis· Nov 24

Regulars· Apr 4

Newcomers· Jul 28

Enlivex terminates securities deal with Rain Foundation

Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

12 Health Care Stocks Moving In Thursday's After-Market Session - Aethlon Medical (NASDAQ:AEMD), Modular

H.C. Wainwright raises Enlivex stock price target to $80 on token gains

Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million

Enlivex Secures $400 Million Premium-Priced Private Placement Backed by RAIN Tokens

Also Discussed

Enlivex Ltd.

Company Information

Location

Enlivex terminates securities deal with Rain Foundation

Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

12 Health Care Stocks Moving In Thursday's After-Market Session - Aethlon Medical (NASDAQ:AEMD), Modular

H.C. Wainwright raises Enlivex stock price target to $80 on token gains

Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million

Enlivex Secures $400 Million Premium-Priced Private Placement Backed by RAIN Tokens

Also Discussed

Social

Jul 28

Bullish· Jul 28

Bearish· Jul 28

Earnings· Mar 25

Announcements· Mar 25

Technical Analysis· Nov 24

Regulars· Apr 4

Newcomers· Jul 28